Chronic Hepatitis B – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Chronic Hepatitis B Market Outlook
Thelansis’s “Chronic Hepatitis B
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Chronic Hepatitis B treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Chronic
Hepatitis B Overview
Chronic
Hepatitis B (CHB) infection is characterized by the presence of Hepatitis B
surface antigen (HBsAg) in the serum for at least six months. Whereas HBsAg
indicates the presence of hepatitis B viral infection, the markers HBeAg and
HBV DNA, as determined by polymerase chain reaction (PCR) assays, are
indicators of viral replication and infectivity. Severe complications
associated with chronic infection encompass cirrhosis, liver failure,
hepatocellular carcinoma, and mortality. In a minority of cases, HBV DNA can be
detected in the serum without concurrent HBeAg presence. This phenomenon is
attributed to the “pre-core” mutant, which impedes the production and release
of the “e” antigen, despite ongoing HBV DNA replication and is associated with
progressive liver disease. Following an acute HBV infection, the risk of
developing chronic hepatitis B varies with age; less than 5% of adults develop
chronic illnesses, whereas 90% of infants do so. Significant long-term
complications like chronic hepatitis, cirrhosis, or hepatocellular carcinoma
(HCC) can result from HBV transmission in children aged five and under.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment